We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute
News

InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute

InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute
News

InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InNexus Biotechnology Inc. , a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology has announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

“Under the existing collaborative agreement, the NCI will continue to evaluate our proprietary technology as applied to certain immunotoxins currently in development at the NCI,” said Dr. Thomas Kindt, Chief Scientific Officer of InNexus.

“Under the amended agreement we will receive additional immunotoxins for modification in our own facilities to enhance activity and function and the NCI will evaluate the modified immunotoxins against unmodified product,” Dr. Kindt added.

Jeff Morhet, InNexus CEO, said, “Work will now be conducted in both houses, and our R&D effort is expanded. Our scientists are excited to apply InNexus technology to the NCI’s anti-cancer compounds (immunotoxins) in our laboratories. These modified products will be tested by the NCI for activity against tumor cells in comparison with the unmodified compounds giving independent evaluation of our new technology.”

Advertisement